Targeted Therapy Combinations: VVIP, VIPOR, and VIPOR-P Clinical Trials
This event was recorded on April 10th, 2024.
In this podcast episode, Dr. Christopher Melani shares about three important trials he has been working on at The National Institute of Health in Bethesda, Maryland. The VVIP, VIPOR, and VIPOR-P studies are targeted therapy combinations that could be the future of lymphoma treatment. We discuss the trial designs, patient eligibility, and how these new treatments could improve lymphoma patient outcomes.
Thank you to our episode sponsors, Regeneron, and Bristol Myers Squibb.
Dr. Christopher Melani
Dr. Melani is a Staff Clinician and a clinical researcher specializing in lymphoma. His areas of interest include the use of novel therapies and drug combinations for the treatment of lymphomas as well as novel methods of molecular monitoring of disease and response to treatment, such as circulating tumor DNA (ctDNA).
Kat Richardson
Kat is from Lehi, Utah and is the Health Education Manager for lymphoma. She has worked in healthcare for a decade now, and earned her degree in Community Health Education and Promotion. Kat is passionate about disease prevention as well as improving quality of life and health equity. She enjoys reading, hiking, baking, ice skating, gardening, time with her family and friends, and most of all, spoiling her nieces and nephew.